The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women with Postmenopausal Osteoporosis

New England Journal of Medicine

Volumn 350, Issue 5, 2004, Pages 459-468

  Meunier, Pierre J ^a   Roux, Christian ^b   Seeman, Ego ^c   Ortolani, Sergio ^d   Badurski, Janusz E ^e   Spector, Tim D ^f   Cannata, Jorge ^g   Balogh, Adam ^h   Lemmel, Ernst Martin ⁱ   Pors Nielsen, Stig ^j   Rizzoli, René ^k   Genant, Harry K ^l   Reginster, Jean Yves ^m  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b René Descartes University ^*  (France)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^e Centre of Osteoporosis and Osteoarticular Diseases   (Poland)

^f ST THOMAS HOSPITAL   (United Kingdom)

^g Central University Hospital of Asturias   (Spain)

^h UNIVERSITY OF DEBRECEN   (Hungary)

ⁱ Max Grundig Clinic   (Germany)

^j HILLERØD HOSPITAL   (Denmark)

^k UNIVERSITY HOSPITAL   (Switzerland)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF LIÈGE   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; STRONTIUM; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE FRAGILITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FEMUR NECK; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSSIFICATION; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; SPINE RADIOGRAPHY; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

ADMINISTRATION, ORAL; AGED; BIOLOGICAL MARKERS; BIOPSY; BONE AND BONES; BONE DENSITY; CALCIUM; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; FEMALE; FEMUR NECK; FRACTURES, SPONTANEOUS; HUMANS; LUMBAR VERTEBRAE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PROSPECTIVE STUDIES; RECURRENCE; RISK; SPINAL FRACTURES; STRONTIUM; THIOPHENES; THORACIC VERTEBRAE; TREATMENT OUTCOME;

EID: 9144233479     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa022436     Document Type: Article

References (31)

1. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fracture with back pain and function: a prospective study. Ann Intern Med 1998;128:793-800.
2. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997;12:24-35.
3. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001;285:320-3.
4. Kotowicz MA, Melton LJ III, Cooper C, Atkinson EJ, O'Fallon WM, Riggs BL. Risk of hip fracture in women with vertebral fracture. J Bone Miner Res 1994;9:599-605.
5. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002;359:1841-50.
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
7. Reginster JY, Minne HW, Sorensen OH, et al. Randomised trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91.
8. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene; results from a 3-year randomized clinical trial. JAMA 1999;282:637-45. [Erratum, JAMA 1999;282:2124.]
9. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene; results from a 3-year randomized clinical trial. JAMA 1999;282:637-45. [Erratum, JAMA 1999;282:2124.]
10. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteopososis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
11. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 2000;27:687-94.
12. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 1997;100:1475-80.
13. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in post-menopausal women with osteoporosis. N Engl J Med 2001;344:1434-41.
14. Marie PJ, Amman P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-9.
15. Marie PJ, Garba MT, Hott M, Miravet L. Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab 1985;11:5-13.
16. Canalis E, Hott M, Deloffre P, Tsouderos Y, Marie PJ. The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro. Bone 1996;18:517-23.
17. Buehler J, Chappuis P, Saffar JL, Tsouderos Y, Vignery A. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001;29:176-9.
18. Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993;8:607-15.
19. Grynpas MD, Marie PJ. Effects of low doses of strontium on bone quality and quantity in rats. Bone 1990;11:313-9.
20. Boivin G, Deloffre P, Perrat B, et al. Strontium distribution and interactions with bone mineral in monkey iliac bone after strontium salt (S 12911) administration. J Bone Miner Res 1996;9:1302-11.
21. Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis - a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002;87:2060-6.
22. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48.
23. Genant HK, Jergas M, Palermo L, et al. Comparison of semiquantitative visual and quantitative morphomertic assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 1996;11:984-96.
24. Wu CY, Li J, Jergas M, Genant HK. Comparison of semiquantitative and quantitative techniques for the assessment of prevalent and incident vertebral fractures. Osteoporos Int 1995;5;354-70.
25. Slosman DO, Provvedini DM, Meunier PJ, et al. The use of different dual X-ray absorptiometry brands in a multicenter clinical trial. J Clin Densitom 1999;2:37-44.
26. Delmas PD. Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos Int 2000;11:Suppl 6:S66-S76.
27. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet 1997;350:550-5.
28. Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone of in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207-15.
29. Nielsen SP, Slosman D, Sorensen OH, et al. Influence of strontium on bone mineral density and bone mineral content measurements by dual X-ray absorptiormetry. J Clin Densitom 1999;2:371-9.
30. Dahl SG, Allain P, Marie PJ, et al. Incorporation and distribution of strontium in bone. Bone 2001;28:446-53.
31. Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial. Osteoporos Int 2002;13:925-31.